

## BLEXIT - best perioperative outcomes from cystectomy

Poster Session 20

Saturday, 25 March  
16:00 - 17:30

**Location:** Room Copenhagen, North Hall (Level 1)

**Chairs:** P. Anderson, Melbourne (AU)  
P. Gontero, Turin (IT)

**Aims and objectives of this session**

To understand how to optimize perioperative outcomes in cystectomy.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 261 **Postoperative psoas muscle loss and nutritional deterioration after radical cystectomy for patients with invasive bladder cancer**  
By: [Miyake M.](#)<sup>1</sup>, Morizawa Y.<sup>1</sup>, Hori S.<sup>1</sup>, Marugami N.<sup>2</sup>, Shimada K.<sup>3</sup>, Gotoh D.<sup>1</sup>, Tatsumi Y.<sup>1</sup>, Nakai Y.<sup>1</sup>, Anai S.<sup>1</sup>, Tanaka N.<sup>1</sup>, Fujimoto K.<sup>1</sup>  
**Institutes:**<sup>1</sup>Nara Medical University, Dept. of Urology, Nara, Japan, <sup>2</sup>Nara Medical University, Dept. of Radiology, Nara, Japan, <sup>3</sup>Nara City Hospital, Dept. of Pathology, Nara, Japan
- 262 **Robot-assisted laparoscopic cystectomy vs. open mini-laparotomy cystectomy: Evaluation of anti-inflammatory potential of CO2-pneumoperitoneum in a randomized porcine study**  
By: [Kingo P.S.](#)<sup>1</sup>, Rasmussen T.M.<sup>1</sup>, Jakobsen L.K.<sup>1</sup>, Palmfeldt J.<sup>2</sup>, Borre M.<sup>1</sup>, Nørregaard R.<sup>2</sup>, Jensen J.B.<sup>1</sup>  
**Institutes:**<sup>1</sup>Aarhus University Hospital, Skejby, Dept. of Urology, Aarhus N, Denmark, <sup>2</sup>Aarhus University Hospital, Skejby, Dept. of Clinical Medicine, Aarhus N, Denmark
- 263 **Withdrawn**  
By:  
**Institutes:**
- 264 **20-gene expression signature to predict lymph node positive disease at radical cystectomy for muscle-invasive bladder cancer: Not validated**  
By: [Van Kessel K.](#)<sup>1</sup>, Van De Werken H.<sup>2</sup>, Lurkin I.<sup>1</sup>, Ziel-Van Der Made A.<sup>1</sup>, Zwarthoff E.<sup>1</sup>, Boormans J.<sup>3</sup>  
**Institutes:**<sup>1</sup>Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, <sup>2</sup>Erasmus MC, Cancer Computational Biology Center (CCBC), Rotterdam, The Netherlands, <sup>3</sup>Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands
- 265 **The use of antibiotic prophylaxis in patients undergoing radical cystectomy for bladder cancer**  
By: [Haider M.](#)<sup>1</sup>, Mayr R.<sup>1</sup>, Fritsche H-M.<sup>1</sup>, Ladurner C.<sup>2</sup>, Pycha A.<sup>2</sup>, Comploj E.<sup>2</sup>, Lemire F.<sup>3</sup>, Lacombe L.<sup>3</sup>, Fradet Y.<sup>3</sup>, Lodde M.<sup>3</sup>  
**Institutes:**<sup>1</sup>University of Regensburg, Dept. of Urology, Regensburg, Germany, <sup>2</sup>General Hospital of Bolzano, Dept. of Urology, Bolzano, Italy, <sup>3</sup>Laval University, Dept. of Urology, Québec, Canada
- 266 **Can radical cystectomy be performed safely in the metastatic setting? Location of metastatic bladder cancer as a determinant of in-hospital mortality**  
By: [Zaffuto E.](#)<sup>1</sup>, Moschini M.<sup>1</sup>, Leyh-Bannurah S-R.<sup>2</sup>, Gazdovich S.<sup>3</sup>, Dell'Oglio P.<sup>1</sup>, Pompe R.<sup>2</sup>, Shariat S.<sup>4</sup>, Montorsi F.<sup>1</sup>, Briganti A.<sup>1</sup>, Saad F.<sup>5</sup>, Karakiewicz P.<sup>3</sup>  
**Institutes:**<sup>1</sup>IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy, <sup>2</sup>Prostate Cancer Center Hamburg-Eppendorf, Martini-Clinic, Hamburg, Germany, <sup>3</sup>University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, <sup>4</sup>Medical University of Vienna, Dept. of Urology, Vienna, Austria, <sup>5</sup>University of Montreal Health

Center, Dept. of Urology, Montreal, Canada

- 267 **Increasing use of incontinent urinary diversion: A total population analysis of radical cystectomies in Germany from 2006 to 2013**  
 By: Groebe C.<sup>1</sup>, Koch R.<sup>2</sup>, Baunacke M.<sup>1</sup>, Wirth M.<sup>1</sup>, Huber J.<sup>1</sup>  
 Institutes:<sup>1</sup>TU Dresden, Medical Faculty Carl Gustav Carus, Dept. of Urology, Dresden, Germany, <sup>2</sup>TU Dresden, Medical Faculty Carl Gustav Carus, Dept. of Medical Statistics and Biometry, Dresden, Germany
- 268 **Incidence and risk factors for venous thromboembolism after transurethral resection of bladder tumor: A population-based analysis**  
 By: Zaffuto E.<sup>1</sup>, Pompe R.<sup>2</sup>, Moschini M.<sup>1</sup>, Bondarenko H.D.<sup>3</sup>, Dell'Oglio P.<sup>1</sup>, Fossati N.<sup>1</sup>, Gandaglia G.<sup>1</sup>, Gallina A.<sup>1</sup>, Shariat S.F.<sup>4</sup>, Montorsi F.<sup>1</sup>, Briganti A.<sup>1</sup>, Karakiewicz P.I.<sup>5</sup>  
 Institutes:<sup>1</sup>IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, <sup>2</sup>Prostate Cancer Center Hamburg-Eppendorf, Martini-Clinic, Hamburg, Germany, <sup>3</sup>University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada, <sup>4</sup>Medical University of Vienna, Dept. of Urology, Vienna, Austria, <sup>5</sup>University of Montreal Health Center, Dept. of Cancer Prognostics and Health Outcomes, Montreal, Canada
- 269 **Diarrhea as a limiting factor of quality of life after radical cystectomy: Results from a cross-sectional study evaluating long-term bowel issues in bladder cancer patients**  
 By: Hupe M.C.<sup>1</sup>, Vahlensieck W.<sup>2</sup>, Hennig M.<sup>1</sup>, Ozimek T.<sup>1</sup>, Struck J.<sup>1</sup>, Tezval H.<sup>3</sup>, Merseburger A.<sup>1</sup>, Kuczyk M.<sup>3</sup>, Kramer M.<sup>1</sup>  
 Institutes:<sup>1</sup>University Hospital Schleswig-Holstein, Campus Luebeck, Dept. of Urology, Luebeck, Germany, <sup>2</sup>Kurpark-Klinik, Dept. of Urology, Bad Nauheim, Germany, <sup>3</sup>Hanover Medical School, Dept. of Urology, Hanover, Germany
- 270 **Low psoas muscle volume indicates long hospitalization after radical cystectomy**  
 By: Kawahara T., Saitoh Y., Miyoshi Y., Uemura H.  
 Institutes:Yokohama City University Medical Center, Dept. of Urology and Renal Transplantation, Yokohama, Japan
- 271 **Efficacy of long acting sandostatin on reducing mucus production in patients with ileal neobladder**  
 By: Khorrami M.H.  
 Institutes:Isfahan University of Medical Sciences, Dept. of Urology, Isfahan, Iran
- 272 **The BAUS radical cystectomy audit 2014/2015 - an update on current practice and an analysis of the effect of centre and surgeon case volume**  
 By: Khadhouri S.<sup>1</sup>, Miller C.<sup>1</sup>, Cresswell J.<sup>2</sup>, Rowe E.<sup>3</sup>, Fowler S.<sup>4</sup>, Hounsome L.<sup>5</sup>, McGrath J.S.<sup>1</sup>  
 Institutes:<sup>1</sup>Royal Devon and Exeter Hospital, Dept. of Urology, Exeter, United Kingdom, <sup>2</sup>South Tees NHS Trust, Dept. of Urology, Middlesbrough, United Kingdom, <sup>3</sup>North Bristol NHS Trust, Dept. of Urology, Bristol, United Kingdom, <sup>4</sup>BAUS, Dept. of Surgery, London, United Kingdom, <sup>5</sup>Public Health England, Dept. of Public Health, London, United Kingdom
- 273 **Pure histological variants are associated with poor survival at radical cystectomy in patients with bladder cancer**  
 By: Moschini M.<sup>1</sup>, Colombo R.<sup>1</sup>, Gandaglia G.<sup>1</sup>, Di Trapani E.<sup>1</sup>, Burgio G.<sup>1</sup>, Damiano R.<sup>2</sup>, Mattei A.<sup>3</sup>, Shariat S.<sup>4</sup>, Salonia A.<sup>1</sup>, Briganti A.<sup>1</sup>, Montorsi F.<sup>1</sup>, Gallina A.<sup>1</sup>  
 Institutes:<sup>1</sup>IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, <sup>2</sup>Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, <sup>3</sup>Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, <sup>4</sup>Medical University of Vienna, Dept. of Urology, Vienna, Austria
- 274 **Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder**  
 By: Seisen T.<sup>1</sup>, Sun M.<sup>1</sup>, Lipsitz S.<sup>2</sup>, Abdollah F.<sup>3</sup>, Leow J.<sup>1</sup>, Menon M.<sup>3</sup>, Von Landenberg N.<sup>1</sup>, Gild P.<sup>1</sup>, Rouprêt M.<sup>4</sup>, Preston M.<sup>1</sup>, Harshman L.<sup>5</sup>, Kibel A.S.<sup>1</sup>, Nguyen P.<sup>6</sup>, Bellmunt J.<sup>5</sup>, Choueiri T.<sup>5</sup>, Trinh Q.-D.<sup>1</sup>  
 Institutes:<sup>1</sup>Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery

and Center For Surgery and Public Health, Boston, United States of America, <sup>2</sup>Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery and Center For, Boston, United States of America, <sup>3</sup>Henry Ford Health System, VUI Center For Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, <sup>4</sup>Pitié-Salpêtrière, APHP, University Paris VI, Dept. of Urology, Paris, France, <sup>5</sup>Dana Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, <sup>6</sup>Brigham and Women's Hospital, Harvard Medical School, Dept. of Radiation Oncology, Boston, United States of America

17:19 - 17:26

### **Summary**

P. Anderson, Melbourne (AU)